Omeros (OMER) Q4 2025 earnings review
Survival Achieved: Novo Deal and FDA Approval Transform Omeros
Omeros executed a textbook corporate turnaround in Q4. After spending 2025 functionally on life support—pausing clinical trials to conserve cash—the company secured a $240 million upfront lifeline by selling zaltenibart to Novo Nordisk and finally won FDA approval for YARTEMLEA. This completely reversed the company's financial trajectory, flipping Q4 Net Income to $86.5 million and eradicating the crippling $67.1 million term loan. The balance sheet is now fortified with $171.8 million in cash. However, with the 'survival' narrative concluded, the company now faces the harsh reality of commercial execution. Launching a specialized therapy into hospital transplant centers will be expensive, and management does not expect to be cash-flow positive until 2027.
🐂 Bull Case
The Novo Nordisk transaction injected $240 million upfront, allowing Omeros to cut total debt by 47% and eliminate restrictive debt covenants. The company is fully funded for the YARTEMLEA launch.
FDA approval for YARTEMLEA arrived with a broad label (adults and children >2 years) and no boxed warnings. As the first and only approved therapy for TA-TMA, the drug has a clear path to market dominance in a high-need, high-mortality indication.
🐻 Bear Case
Omeros has no recent history of self-commercializing a hospital-administered drug. The commercial launch will require heavy SG&A investment, guaranteeing ongoing operating losses despite the recent cash influx.
To survive until the Novo deal, Omeros paused multiple clinical programs in 2025. Restarting these trials will cause an immediate acceleration in cash burn.
⚖️ Verdict: 🟢
Bullish. Management delivered exactly what they promised: a non-dilutive rescue transaction and an FDA approval. The existential risks have been cleared, leaving a well-capitalized company with an approved commercial asset and up to $1.7 billion in potential future Novo Nordisk milestones.
Key Themes
The Novo Nordisk Lifeline Reverses the Balance Sheet
The sale of the zaltenibart (MASP-3) program to Novo Nordisk was the pivotal event of FY25. Omeros received $240 million upfront in November, which it immediately used to wipe out its $67.1 million senior secured term loan (and its attached $25M minimum liquidity covenant) and pay down 2026 convertible notes. This transaction completely reversed Omeros's financial distress, shifting the narrative from impending bankruptcy to a robustly funded commercial launch.
YARTEMLEA Launch Initiated
Accelerating. Following the December 23 approval, Omeros quickly transitioned to commercial distribution in January 2026. The approval is highly favorable: no boxed warning, no REMS, and no required vaccinations. The company's sales force is actively targeting transplant centers. This represents a monumental shift from a clinical-stage biotech to a commercial-stage entity.
Underlying Operations Are Still Burning Cash
While Q4 showed an $86.5 million net income, this was entirely driven by the $237.6 million net gain from the Novo transaction and massive derivative adjustments. Stripping out the transaction gain, Omeros continues to run a structural operating loss. Management explicitly stated they are 'targeting positive cash flow in 2027,' acknowledging that 2026 will be a heavy burn year as they fund the YARTEMLEA launch and reactivate paused clinical programs.
OMIDRIA Royalties Remain Stagnant
Stable to slightly decelerating. Q4 OMIDRIA royalties from Rayner Surgical came in at $9.2 million on U.S. net sales of $30.7 million, down slightly from $10.1 million on $33.6 million in sales in the prior year quarter. This legacy asset provides a steady but non-growing baseline of cash while YARTEMLEA spins up.
Other KPIs
Decelerating. Down significantly from $119.5 million in FY24. However, this is an artificial decline. Management actively 'paused' major trials (like zaltenibart and OMS1029) to conserve cash to survive until the Novo deal closed. Investors should expect a sharp rebound in R&D in FY26 as the deep pipeline is reactivated.
Decelerating. Down from $47.4 million in FY24, again reflecting survival-mode cash conservation. Like R&D, this will reverse course immediately in 2026 as Omeros funds its national commercial field force for YARTEMLEA.
Guidance
Accelerating timeline expectation. Management targets becoming cash flow positive in 2027. This implies they believe YARTEMLEA revenue, combined with potential near-term Novo milestones ($100 million in near-term eligibility), will overtake operating burn within 18-24 months.
The European Medicines Agency is reviewing the Marketing Authorization Application for TA-TMA, offering a potential catalyst for European commercialization or ex-US partnership monetization in the second half of 2026.
Management plans to repay the remaining aggregate principal amount of its 2026 convertible notes at maturity in February 2026 using cash on hand, effectively cleaning up all near-term debt.
Key Questions
Launch Trajectory and SG&A Ramp
With the YARTEMLEA launch now underway, what is the anticipated scale of the SG&A step-up in Q1 and Q2 2026? How quickly do you expect to penetrate the 175 targeted transplant centers?
Restarting the Paused Pipeline
Now that capital is secured, what is the timeline and prioritized order for restarting the clinical programs that were placed on hold in 2025, specifically OMS1029?
Novo Nordisk Milestones
The agreement includes up to $100 million in 'near-term' milestones. Can management provide any color on the specific triggers for these milestones and whether any are expected to hit in FY26?